Design Therapeutics Statistics
Share Statistics
Design Therapeutics has 56.77M
shares outstanding. The number of shares has increased by 0.47%
in one year.
Shares Outstanding | 56.77M |
Shares Change (YoY) | 0.47% |
Shares Change (QoQ) | 0.25% |
Owned by Institutions (%) | 99.99% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 38 |
FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 3.69M, so 6.5% of the outstanding
shares have been sold short.
Short Interest | 3.69M |
Short % of Shares Out | 6.5% |
Short % of Float | 9.85% |
Short Ratio (days to cover) | 36.31 |
Valuation Ratios
The PE ratio is -7.04 and the forward
PE ratio is -3.26.
Design Therapeutics's PEG ratio is
0.27.
PE Ratio | -7.04 |
Forward PE | -3.26 |
PS Ratio | 0 |
Forward PS | 4.2 |
PB Ratio | 1.44 |
P/FCF Ratio | -8.04 |
PEG Ratio | 0.27 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Design Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.31,
with a Debt / Equity ratio of 0.01.
Current Ratio | 29.31 |
Quick Ratio | 29.31 |
Debt / Equity | 0.01 |
Debt / EBITDA | -0.05 |
Debt / FCF | -0.05 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-885,500 |
Employee Count | 56 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -1.23% in the
last 52 weeks. The beta is 1.62, so Design Therapeutics's
price volatility has been higher than the market average.
Beta | 1.62 |
52-Week Price Change | -1.23% |
50-Day Moving Average | 3.77 |
200-Day Moving Average | 4.92 |
Relative Strength Index (RSI) | 54.38 |
Average Volume (20 Days) | 131,961 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -62.38M |
Net Income | -49.59M |
EBITDA | -48.99M |
EBIT | -49.59M |
Earnings Per Share (EPS) | -0.88 |
Full Income Statement Balance Sheet
The company has 22.56M in cash and 2.33M in
debt, giving a net cash position of 20.23M.
Cash & Cash Equivalents | 22.56M |
Total Debt | 2.33M |
Net Cash | 20.23M |
Retained Earnings | -227.21M |
Total Assets | 237.47M |
Working Capital | 225.41M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -43.1M
and capital expenditures -340K, giving a free cash flow of -43.45M.
Operating Cash Flow | -43.1M |
Capital Expenditures | -340K |
Free Cash Flow | -43.45M |
FCF Per Share | -0.77 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |